NCT00737555View on ClinicalTrials.gov

A Study of the Safety and Tolerability of the Addition of CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions

Solid Tumor

Interventions

DRUG

CHR-2797

Oral once daily administration of capsules of CHR-2797, to determine safety and tolerability in patients being treated with paclitaxel infusion every 3 weeks for up to 18 weeks.

Trial Locations (2)

6525 GA

UMC St Radboud, Nijmegen

3015 CE

Erasmus MC University Medical Centre- Location Centrum, Rotterdam